<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01233128</url>
  </required_header>
  <id_info>
    <org_study_id>VEGF &amp; LOC387715/HTRA1</org_study_id>
    <nct_id>NCT01233128</nct_id>
  </id_info>
  <brief_title>Vascular Endothelial Growth Factor (VEGF) &amp; LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy</brief_title>
  <official_title>Association of Vascular Endothelial Growth Factor and LOC387715/HTRA1 Polymorphisms With the Response to Intravitreal Ranibizumab Injections in Polypoidal Choroidal Vasculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyungpook National University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyungpook National University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate whether there is an association of the LOC387715/HTRA1 and
      vascular endothelial growth factor polymorphism with response to treatment with intravitreal
      ranibizumab injections for patients with polypoidal choroidal vasculopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective comparative case series comprised of 70 patients being treated for
      polypoidal choroidal vasculopathy with intravitreal ranibizumab injections and 112 control
      subjects. Patients were genotyped for the LOC387715 (rs10490924), HTRA1 gene (rs11200638),
      and VEGF (rs3025039 and rs833069)polymorphism using Real-Time polymerase chain reaction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Best-corrected visual acuity</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Best-corrected visual acuity (BCVA) using the Snellen chart was evaluated including BCVA before treatment and BCVA up to 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Angiographic characteristics</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Fluorescein angiography (FA) and ICGA (HRA; Heidelberg Engineering, Dossenheim, Germany)were evaluated. Greatest linear dimension (GLD) was determined based on both FA and ICGA.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">121</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>polypoidal choroidal vasculopathy</arm_group_label>
    <description>patients who were treated for polypoidal choroidal vasculopathy with intravitreal injections of 0.5 mg of ranibizumab monthly for 3 months</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Genomic DNA was extracted from peripheral blood with the Qiagen QIAamp Blood Kit (Qiagen,
      Valencia, CA).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The authors did a retrospective chart review of 70 patients with PCV who visited the
        Department of Ophthalmology, Kyungpook National University Hospital in Daegu, Korea.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients older than 60 years of age at onset

          -  polyp-like terminal aneurysmal dilations with or without branching vascular networks
             in ICGA and subretinal reddish-orange protrusions corresponding to polyp-like lesions

          -  patients who had intravitreal injections of 0.5 mg of ranibizumab monthly for 3 months

        Exclusion Criteria:

          -  patients with retinal or choroidal diseases including pathologic myopia, angioid
             streaks, idiopathic choroidal neovascularization (CNV), presumed ocular
             histoplasmosis, and other secondary CNV

          -  patients who refused genotypic analyses
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>In Taek Kim, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>In Taek Kim</name>
      <address>
        <city>Daegu</city>
        <state>Kyungsangpookdo</state>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://ghr.nlm.nih.gov/</url>
    <description>genetics home reference</description>
  </link>
  <reference>
    <citation>Immonen I, Seitsonen S, Tommila P, Kangas-Kontio T, Kakko S, Savolainen ER, Savolainen MJ, Liinamaa MJ. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. Ophthalmology. 2010 Jan;117(1):103-8. doi: 10.1016/j.ophtha.2009.06.037. Epub 2009 Nov 6.</citation>
    <PMID>19896188</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2010</study_first_submitted>
  <study_first_submitted_qc>November 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2010</study_first_posted>
  <last_update_submitted>April 6, 2012</last_update_submitted>
  <last_update_submitted_qc>April 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyungpook National University</investigator_affiliation>
    <investigator_full_name>Dong Ho Park</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

